Severe mitral valve regurgitation with fatal cardiogenic shock in a patient on long-term cabergoline treatment

International Journal of Cardiology

Volumn 133, Issue 3, 2009, Pages

  Luedde, M ^a   Helmke, B ^a   Katus, H A ^a   Frey, N ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Ergoline dopamine agonists; Mitral valve insufficiency; Parkinson's disease

Indexed keywords

ANOREXIGENIC AGENT; CABERGOLINE; ERGOLINE DERIVATIVE;

AGED; ANAMNESIS; AORTA BALLOON; ARTICLE; CARDIOGENIC SHOCK; CASE REPORT; CLINICAL FEATURE; ECHOCARDIOGRAPHY; FEMALE; HEART CATHETERIZATION; HUMAN; HUMAN TISSUE; LONG TERM CARE; MITRAL VALVE REGURGITATION; PARKINSON DISEASE; PRIORITY JOURNAL; CHEMICALLY INDUCED; COMPLICATION; FATALITY; MITRAL VALVE INSUFFICIENCY; SHOCK, CARDIOGENIC;

AGED; ERGOLINES; FATAL OUTCOME; FEMALE; HUMANS; LONG-TERM CARE; MITRAL VALVE INSUFFICIENCY; SHOCK, CARDIOGENIC;

EID: 63149158721     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2007.11.043     Document Type: Article

References (4)

1. Van Camp G., Flamez A., Cosyns B., et al. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 363 9416 (2004) 1179-1183
2. Schade R., Andersohn F., Suissa S., Haverkamp W., and Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 356 1 (2007) 29-38
3. Zanettini R., Antonini A., Gatto G., Gentile R., Tesei S., and Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 356 1 (2007) 39-46
4. Martin M., Iglesias-Cubero G., Diaz Molina B., and Moris De la Tassa C. Mitral heart disease due to cabergoline. Int J Cardiol 114 1 (2007 Jan 2) e7-e8